March 15, 2018 – By Linda Rogers
Among 19 analysts covering 3D Systems Corporation (NYSE:DDD), 2 have Buy rating, 6 Sell and 11 Hold. Therefore 11% are positive. 3D Systems Corporation has $22 highest and $6 lowest target. $12.53’s average target is -6.07% below currents $13.34 stock price. 3D Systems Corporation had 63 analyst reports since July 22, 2015 according to SRatingsIntel. The stock of 3D Systems Corporation (NYSE:DDD) has “Hold” rating given on Wednesday, August 2 by Canaccord Genuity. The stock of 3D Systems Corporation (NYSE:DDD) has “Hold” rating given on Wednesday, August 2 by Stifel Nicolaus. As per Thursday, March 1, the company rating was maintained by FBR Capital. FBR Capital maintained it with “Sell” rating and $7.0 target in Wednesday, November 8 report. The rating was maintained by Goldman Sachs on Tuesday, March 15 with “Neutral”. Canaccord Genuity maintained 3D Systems Corporation (NYSE:DDD) on Monday, May 29 with “Hold” rating. On Friday, July 31 the stock rating was maintained by UBS with “Sell”. The firm has “Hold” rating given on Monday, July 24 by Loop Capital Markets. The rating was maintained by Piper Jaffray with “Underweight” on Tuesday, July 4. JP Morgan downgraded 3D Systems Corporation (NYSE:DDD) on Tuesday, March 15 to “Underweight” rating.
Celldex Therapeutics Inc (NASDAQ:CLDX) had an increase of 3.48% in short interest. CLDX’s SI was 7.51M shares in March as released by FINRA. Its up 3.48% from 7.26 million shares previously. With 1.12M avg volume, 7 days are for Celldex Therapeutics Inc (NASDAQ:CLDX)’s short sellers to cover CLDX’s short positions. The SI to Celldex Therapeutics Inc’s float is 5.86%. The stock decreased 1.18% or $0.03 during the last trading session, reaching $2.52. About 671,838 shares traded. Celldex Therapeutics, Inc. (NASDAQ:CLDX) has declined 20.62% since March 15, 2017 and is downtrending. It has underperformed by 37.32% the S&P500.
Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company has market cap of $355.51 million. The Company’s drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; and Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient’s immune response against cancer. It currently has negative earnings. It also develops earlier stage drug candidates in clinical development, including CDX-1401, an immunotherapeutic for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers.
Among 13 analysts covering Celldex Therapeutics (NASDAQ:CLDX), 8 have Buy rating, 0 Sell and 5 Hold. Therefore 62% are positive. Celldex Therapeutics had 26 analyst reports since August 11, 2015 according to SRatingsIntel. Jefferies downgraded the stock to “Hold” rating in Tuesday, March 8 report. Jefferies maintained Celldex Therapeutics, Inc. (NASDAQ:CLDX) on Monday, June 12 with “Hold” rating. The rating was maintained by H.C. Wainwright with “Buy” on Tuesday, March 8. On Tuesday, August 1 the stock rating was reinitiated by H.C. Wainwright with “Buy”. Leerink Swann maintained the stock with “Market Perform” rating in Thursday, March 8 report. TH Capital maintained it with “Buy” rating and $39 target in Tuesday, August 11 report. On Monday, March 7 the stock rating was downgraded by Wedbush to “Neutral”. The stock of Celldex Therapeutics, Inc. (NASDAQ:CLDX) has “Neutral” rating given on Monday, March 7 by Guggenheim. Cantor Fitzgerald maintained Celldex Therapeutics, Inc. (NASDAQ:CLDX) on Friday, February 26 with “Buy” rating. Jefferies maintained it with “Hold” rating and $3.0 target in Thursday, March 8 report.
3D Systems Corporation, through its subsidiaries, provides 3D printing services and products worldwide. The company has market cap of $1.52 billion. The company’s 3D printers transform data input generated by 3D design software, CAD software, or other 3D design tools into printed parts using a range of print materials, including plastic, nylon, metal, composite, elastomeric, wax, polymeric dental materials, and Class IV bio-compatible materials. It currently has negative earnings. It offers various 3D printing technologies, such as stereolithography, selective laser sintering, direct metal printing, multijet printing, and colorjet printing.
The stock increased 9.79% or $1.19 during the last trading session, reaching $13.34. About 5.21M shares traded or 73.33% up from the average. 3D Systems Corporation (NYSE:DDD) has risen 77.31% since March 15, 2017 and is uptrending. It has outperformed by 60.61% the S&P500.
Investors sentiment decreased to 0.99 in 2017 Q3. Its down 0.42, from 1.41 in 2017Q2. It fall, as 31 investors sold 3D Systems Corporation shares while 43 reduced holdings. 29 funds opened positions while 75 raised stakes. 66.82 million shares or 4.62% more from 63.87 million shares in 2017Q2 were reported. Thrivent For Lutherans reported 0% in 3D Systems Corporation (NYSE:DDD). Stifel Finance reported 17,414 shares. Wells Fargo Co Mn, California-based fund reported 167,914 shares. Int Gru stated it has 306,119 shares. Tower Research (Trc) accumulated 6,207 shares. Oregon Employees Retirement Fund reported 0.01% of its portfolio in 3D Systems Corporation (NYSE:DDD). Invesco reported 0% of its portfolio in 3D Systems Corporation (NYSE:DDD). Ameritas Invest Ptnrs reported 40,994 shares. Moreover, Commerzbank Aktiengesellschaft Fi has 0.11% invested in 3D Systems Corporation (NYSE:DDD). Barclays Public Ltd Co holds 230,637 shares. Quantbot Tech L P has invested 0.03% of its portfolio in 3D Systems Corporation (NYSE:DDD). Winfield Associates Inc stated it has 0% in 3D Systems Corporation (NYSE:DDD). Evercore Wealth Ltd Com has 0% invested in 3D Systems Corporation (NYSE:DDD). Sg Americas Secs Limited Liability Corp owns 135,934 shares. Private Advisor Group Limited Liability Corp owns 15,809 shares.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.
By1 Linda Rogers